Johnson & Johnson has announced early outcomes from the OMNY-AF pilot study at the 2026 AF Symposium. The study evaluated the investigational OMNYPULSE Platform for the treatment of symptomatic paroxysmal atrial fibrillation (AFib). In the 30-patient pilot cohort, investigators reported 100% acute procedural success with no procedure-related adverse events. At 12 months, 90% of patients achieved primary effectiveness, and 56.7% of cases were performed with zero fluoroscopy. Additional data on the VARIPULSE Platform highlighted a low neurovascular event rate of 0.22% in 6,811 patients following workflow enhancements and an optimized irrigation flow rate. These results were presented at the 2026 AF Symposium.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Johnson & Johnson published the original content used to generate this news brief on February 06, 2026, and is solely responsible for the information contained therein.